Company performance
Add to research
Current Price
as of Feb 14, 2025$6.24
P/E Ratio
N/A
Market Cap
$279.48M
Description
Add to research
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Metrics
Add to research
Overview
- HQNew York, NY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerYMAB
- Price$6.24+1.13%
Trading Information
- Market cap$279.48M
- Float76.13%
- Average Daily Volume (1m)567,548
- Average Daily Volume (3m)415,725
- EPS-$0.54
Company
- Revenue$84.55M
- Rev growth (1yr)-9.74%
- Net income-$7.00M
- Gross margin87.82%
- EBITDA margin-45.76%
- EBITDA-$8.45M
- EV$519.80M
- EV/Revenue6.15
- P/EN/A
- P/S3.29
- P/B3.02
- Debt/Equity1.16
Documents
Add to research
SEC Filings
Earnings Calls
Factset Street Account